Influence of different treatment modalities on survival of patients with low-grade endometrial stromal sarcoma: A retrospective cohort study. (November 2015)

• Record Type: Journal Article
• Authors: Zhou, Juan; Zheng, Hua; Wu, San-Gang; He, Zhen-Yu; Li, Feng-Yan; Su, Guo-Qiang; Sun, Jia-Yuan
• Is Part Of: International journal of surgery. Volume 23:Part A(2015)
• Page Start: 147
• Page End: 151
• Publication Date: 2015-11
• Subjects: Low-grade endometrial stromal sarcoma -- Prognosis -- Treatment -- Lymphadenectomy -- Ovarian preservation; Surgery -- Periodicals; Surgical Procedures, Operative -- Periodicals; 617.005
• DOI: 10.1016/j.ijsu.2015.09.072
• Languages: English
• ISSNs: 1743-9191

Abstract

Abstract: Background: To assess the efficacy of different treatment modalities on the outcome of patients with low-grade endometrial stromal sarcoma (LG-ESS). Methods: Patients with LG-ESS who received hysterectomy from March 1991 to December 2013 were retrospectively analyzed. The associations between clinicopathologic variables and disease free survival (DFS) were evaluated. Results: One hundred and fourteen patients met the eligibility requirements. All patients received hysterectomy as the main treatment, 17.5% (20/114) of patients received ovarian preservation, and 62.3% (71/114) of patients received lymphadenectomy. Fifty-six patients received chemotherapy, 36 patients received radiotherapy, and 11 patients received endocrine therapy. The median follow-up duration was 40 months. The 5-year and 10-year DFS rates were 91.8% and 77.4%, respectively. The 5-year and 10-year overall survival rates were 96.7% and 96.7%, respectively. Univariate analyses showed that there were no risk factors associated with DFS. Lymphadenectomy, lymph node status, ovarian preservation, chemotherapy, radiotherapy, and endocrine therapy had no significant effect on DFS. Conclusions: Hysterectomy has been the mainstay of treatment for LG-ESS. The optimal treatment strategy in LG-ESS remains to be determined. Highlights: Hysterectomy has been the mainstay of treatment for LG-ESS. Hysterectomy results in excellent overall survival. Optimal adjuvant treatment strategy for LG-ESS is still controversial.